An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease|
- Number of Subjects With at Least One Adverse Event During This Open-label Extension Study [ Time Frame: six years ]Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
- Number of Subjects Who Withdrew From the Trial Due to an Adverse Event [ Time Frame: six years ]Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
- Mean Epworth Sleepiness Scale Score During the Open-label Extension [ Time Frame: Visit 10 (end of year 1), Visit 14 (end of year 2), Visit 18 (end of year 3), Visit 22 (end of year 4), Visit 26 (end of year 5), Visit 30 (end of year 6), End of Treatment (last study visit or early withdrawal visit) ]The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.
|Study Start Date:||August 2002|
|Study Completion Date:||December 2008|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
Rotigotine trans-dermal patches, once daily:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);
During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.
After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
Other Name: Neupro®
Please refer to this study by its ClinicalTrials.gov identifier: NCT00599196
Hide Study Locations
|East Gosford, Australia|
|Brno, Czech Republic|
|Ostrava, Czech Republic|
|Plzen, Czech Republic|
|Aix-en -Provence, France|
|Caen Cedex, France|
|Toulouse Cedex, France|
|Tel Aviv, Israel|
|Auckland, New Zealand|
|Christchurch, New Zealand|
|North Shore, New Zealand|
|Wellington, New Zealand|
|Mosina k/Poznania, Poland|
|Cape Town, South Africa|
|Pretoria, South Africa|
|Birmingham, United Kingdom|
|Blackpool, United Kingdom|
|Glasgow, United Kingdom|
|Liverpool, United Kingdom|
|London, United Kingdom|
|Newcastle Upon Tyne, United Kingdom|
|Swansea, United Kingdom|
|Study Director:||UCB Clinical Trial Call Center||+1 877 822 9493 (UCB)|